Clinical Trial Update: Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

View source ↗

Summary

Pfizer's infliximab biosimilar was studied in a Drug Use Investigation for psoriasis indications; the trial has completed and results were posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythrodermic Psoriasis
• Psoriasis
• Psoriatic Arthritis
• Pustular Psoriasis

Drugs mentioned

• Ixifi (infliximab biosimilar)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis Vulgaris, Psoriasis Arthropathica | Status: COMPLETED | Results posted: 2025-06-19